Article

NASP Launches Website to Combat Harmful DIR Fees Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. Treatment-Resistant Breast Cancer May Have Met Its Match with First-In-Class Drugs

The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer. Read more…

4. Influenza Triggers Relapse in Multiple Sclerosis

Upper respiratory infections cause immune cells to travel to the brain, prompting multiple sclerosis to relapse. Read more…

3. FDA Approves Acute Lymphoblastic Leukemia Drug

Inotuzumab ozogamicin (Besponsa) granted FDA approval to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read more…

2. Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis

Research finds that a robust pipeline of PsA agents will put pressure on Cosentyx. Read more…

1. NASP Launches Website to Combat Harmful DIR Fees

StopDIRfees.com provides education about direct and indirect remuneration fees. Read more…

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards